A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma

G. Garcia, A. Magnan, R. Chiron, P.O. Girodet, V. Le Gros, M. Humbert (Clamart, Nantes, Montpellier, Bordeaux, Rueil-Malmaison, France)

Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Session: Clinical diagnosis and treatment of adult asthma
Session type: Oral Presentation
Number: 4692
Disease area: Airway diseases

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Garcia, A. Magnan, R. Chiron, P.O. Girodet, V. Le Gros, M. Humbert (Clamart, Nantes, Montpellier, Bordeaux, Rueil-Malmaison, France). A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma. Eur Respir J 2012; 40: Suppl. 56, 4692

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012


Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients
Source: Eur Respir J, 58 (6) 2101702; 10.1183/13993003.01702-2021
Year: 2021



A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma
Source: Eur Respir J, 51 (1) 1701126; 10.1183/13993003.01126-2017
Year: 2018



Metabolomic approach in the characterization of omalizumab responders and non-responders among children with severe asthma: a multicenter prospective study.
Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections
Year: 2021



A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis
Source: Eur Respir J , 49 (3) 1602486; DOI: 10.1183/13993003.02486-2016
Year: 2017


A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers
Source: Eur Respir J 2001; 18: Suppl. 33, 482s
Year: 2001

A randomised controlled trial of zafirlukast in acute asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 254s
Year: 2005

Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 547s
Year: 2007

Towards optimal patient selection for bronchial thermoplasty treatment in severe asthma: results from the TASMA randomized trial
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019


Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021


Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012

The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Exercise and diet improve asthma controlin non-obese asthma patients -  a randomised controlled trial
Source: International Congress 2017 – Notable abstracts in asthma
Year: 2017



Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021


Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003

Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019